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Ttm most appropiate management for bronchial asthma
is the control ofairway inflammation. Corticosteroids are
the most effective anti-inflammatory drugs available, but
they have a number of side effects; most of these are
dose-dependent. In children, asthma control should be
accomplished with low steroid doses possibly given by
inhalation. In a double-bind placebo-controlled cross-
over study a group of children with mild to moderate
asthma received NED 16 rag/day or BDP 400 [tg/day. Val-
ues for FEVl, PEF, symptoms use ofbronchodilators over-
lapped, whereas bronchial hyper-responsiveness as-
sessed by histamine bronchoprovocation challenge was
better with BDP than NED. In another case, one boy with
high bronchial hyper-reactivity assessed by provocation
test with hypertonic solution, experienced a significant
improvement only after 2 weeks of therapy with
Deflazacort (2 mg/Kg/day) followedby 4 months on com-
bined treatment with NED (16 mg/day) and BDP (300
day). Authors conclude that NED could have a steroid-
sparing effect over long-term use.
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It is now clear that the most appropriate manage-
ment of bronchial asthma is to control airway inflam-
mation. 1," The drugs able to reduce inflammation in
asthmatic children are in the following order of
decreasing activity: systemic steroids; inhaled ster-
oids (IS); nedrocromil sodium (NED); sodium
cromoglycate (SGC); and probably ketotifen.-s
The anti-inflammatory role of the new long-acting
beta-2 agonist, salmeterol, has not been established
because a 12-week treatment period of doses effec-
tive in controlling symptoms did not show any sig-
nificant effect on mast cells, eosinophils, T-cells or
the epithelium of bronchial mucosa and sub-
mucosa.6
Anti-inflammatory drugs and mild-to-
moderate asthma
The international guidelines about asthma man-
agement suggest regular anti-inflammatory therapy
should be given in mild persistent, moderate and
severe asthma. Only mild episodic asthma should be
treated exclusively with environmental control and
beta-2 agonist on demand. However, it is not certain
which anti-inflammatory agent should be used as
first-line therapy.7-9
Corticosteroids are the most effective anti-inflam-
matory drugs, but they have a number of side effects
(Tables 1 and 2). Inhaled steroid therapy is effective
in controlling asthma without the side effects associ-
ated with systemic administration, although recent
reports have shown that the dose of 400 mcg/day is
not ’safe’, since growth may be affected,
1 the
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Table 1. Side effects of inhaled corticosteroids
Local side effects
Cough
Bronchostenosis
Oral candidosis
Atrophic glossitis
Haemorrhagic angina
Dysphonia
Chronic oesophagitis
Laryngeal candidosis
Table 2. Side effects of inhaled corticosteroids
Systemic side effects
HPA suppression
Growth delay in asthmatic children
Interference in bone formation
Reduction of circulating eosinophils and lymphocytes
Metabolic effects
Cataract
Cushing syndrome faeces
Derma thinning
Purpura
hypophysio-pituitary-adrenal axis may be sup-
pressed11,1" and bone metabolism may be influ-
enced. 13
Sodium cromoglycate (SCG) may be the drug of
choice in children with mild-to-moderate asthma,
because of its optimal ratio between effectiveness
and safety. TM SCG is able to control both clinical
symptoms and bronchial hyper-responsiveness; it is
also active in reducing the number of inflammatory
cells in the asthmatic airway. 15-18 SGC is equally
effective as low doses of inhaled steroids, but has the
advantage of being safer.19-2
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Table 3. Clinical features of children recruited for the trial in
treatment group 1"
Age, mean (range)
Sex
FEVl %, mean (range)
% Reversibility
after Beta-2, mean (range)
PC20 Histamine, mean (range)
Allergic asthma
10.46 (8-13 years)
7 F and 8 M
73.39 (70.2-79.1)
19.76 (16.7-22.5)
670 (250-1200)
15/15 (Dermat. +++)
*Trial started with BDP 400 mcg/day + placebo for 6 weeks, then
cross-over with nedocromil sodium 16 mg (NED) + placebo.
Table 4. Clinical features of children recruited for the trial in treat-
ment group 2*
Age, mean (range)
Sex
FEVl % mean (range)
% Reversibility
after Beta-2, mean (range)
PC20 Histamine, mean (range)
Allergic asthma
10.6 (8-13 years)
5 F and 10 M
70.02 (69.3-78.5)
19.56 (16.7-22.7)
653 (400-1000)
13/15 (Dermat. +++)
*Trial started with NED 16 mg/day + placebo for 6 weeks, then
cross-over with BDP 400 mcg/day + placebo.
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FIG. 1. BDP vs. nedocromil. A FEV1 (mean change from baseline) in the and groups treated.
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FIG. 2. BDP vs. nedocromil./ PEF (mean change from baseline) in the and II groups treated.
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FIG. 3. BDP vs. nedocromil. A Symptoms score (mean change from baseline) in the and groups treated.
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FIG. 4. BDP vs. nedocromil. A Symptoms score (mean change from baseline) in the and II groups treated.
"l’abl 5. Nedocromil sodium and steroids: reduction of
corticosteroids therapy in adult asthmatic patients
Authors
(ref)
Treatment duration Nedocromil Steroid-sparing
(weeks) (dose, mg) effect
Bone et al. (25) 4
Svendsen and 8
Jorgensen (26)
Orefice et aL (27) 12
Paananen et al. (28) 12
Ruffin et al. (29) 4
Goldin and 20
Bateman (30)
Wong et al. (31) 16
Boulet et al. (32) 12
16 yes
16 no
16 yes
16 no
16 yes
16 no
16 yes
16 no
Nedocromil sodium (NED) has been shown to be
equally or more effective than SCG as an anti-inflam-
matory agent, especially in intrinsic asthma. 22-24 In
this paper, we report the results of a double-blind
cross-over study comparing the effects of NED (16
mg/day) and BDP (400 mcg/day) on symptoms and
bronchial hyper-responsiveness in 30 children with
moderate asthma (Tables 3 and 4, and Figs 1-6). The
patients had a wash-out off-therapy period for a
minimum of 2 months. After a 2-week run-in period,
children were randomly allocated to two similar
treatment groups (Tables 3 and 4), receiving BDP
(400 mcg/day) + placebo or NED (16 mg/day) +
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FIG. 5. BDP vs. nedocromil. A n puff/die of Beta2 (mean change from baseline) in the and II groups treated.
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FIG. 6. BDP v& nedocromil. A PC 20 Histamine (mean change from baseline) in the and II groups treated.
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FIG. 9. Hyperosmolar solution challenge after 2 weeks’ therapy with
Deflazacort.
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FIG. 10. Hyperosmolar solution challenge after 4 months’ theapy with NED
+ BDP.
placebo, respectively, for 6 weeks in a cross-over
design. Assessment was made by diary cards,
bronchodilator use and intermittent clinical evalua-
tion, spirometry and histamine bronchoprovocation
challenge (at baseline and after 3, 6, 9 and 12 weeks).
No significant difference (t-test analysis) was found
between the two treatment groups (Figs 1-5),
except that the PC20 histamine was significantly
higher after 6 weeks in the corticosteroid group (p >
0.05) (Fig. 6).
Our study also showed that NED is not effective
before 4 weeks of treatment. Furthermore, in an
unpublished follow-up study, we found that the
highest values of FEV1 occurred after 3 months of
continuous treatment with NED.
In moderate to severe asthma, anti-inflammatory
therapy with SCG or NED should be reinforced by
increasing doses (i.e. SCG 40 mg x 4 times/day) and/
or by increasing the times of administration23 and/or
by adding inhaled steroids. Dose adjustments of
inhaled steroids should be made on the basis of
clinical response, but high doses are not usually
required because of the steroid sparing effect of SCG
and NED.
It has been demonstrated that NED (16 mg/day)
could replace BDP (330 mcg/day).25 When overall
control of asthma is achieved, inhaled steroids
should be gradually reduced until the lowest effec-
tive dose is found or until their gradual but complete
withdrawal.
Figures 7-10 show the results of provocation tests
with hypertonic solution by monitoring
and pco with Gasthmatic, in an 8-year-old boy
with moderate allergic asthma. The hyperosmolar
solution challenge was performed with increasing
concentrations of NaCl solution (2.3-4.6-9.2-18.4%)
administered by ultrasonic nebuliser. At baseline, the
patient already expressed significant derangements
in PO and PCO on inhalation of normosmolar
solution (Fig. 7). Two months after NED (16 mg/day),
the findings were unchanged (Fig. 8). Fourteen days
on Deflazacort (2 mg/Kg/day) brought about a re-
duction in bronchial inflammation (Fig. 9). The chal-
lenge became negative after four months of treat-
ment with NED (16 mg/day)+BDP (300 mg/day)
(Fig.10).
Anti-inflammatory Drugs and Severe
Asthma
In severe asthma, which is fortunately rare in
childhood, corticosteroids are widely accepted as a
first-line therapy. When control of asthma appears to
require continuous treatment with steroids, an alter-
native diagnosis should be first suspected, since a
number of non-asthmatic conditions may cause
wheezing or dyspnea (i.e. cystic fibrosis, congenital
heart disease, recurrent aspiration).
When the diagnosis of asthma is certain, all the
precipitating trigger factors (such as food allergens,
cigarette smoke, occupational and environmental ex-
posure, chronic sinusitis) should be identified and
removed where possible. Before starting with steroid
therapy, it is also necessary to control the adequacy
of the previous therapeutic regimen, ensure the pa-
tient’s compliance, and to control the inhalation
technique and the aerosol delivery system output.
In cases requiring the use of steroids, inhaled
steroids are the first choice treatment. However, the
therapeutic effects of inhaled steroids are dose-de-
pendent, high-dose inhaled steroid therapy shows an
increased risk of side effects, including adrenal and
growth suppression.
11,1"
The minority of asthmatic children continuing to
have an inadequate response to inhaled steroids
need to go on to have oral administration. Oral
steroids should be used at the lowest effective dose
possible and be given on alternate days. The ability
of SCG and NED in reducing steroid requirements in
steroid-dependent asthmatic patients .is controversial,
as shown in Table 5.25-3 Dissimilar results in different
trials could depend on the early suspension of ster-
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inhaled steroids after their withdrawal, which lasts
for about 3 months. 34 In asthmatic children who are
dependent on oral steroids, drugs such as
troleandomicin,35 methotrexate,36 cyclosporin,37 and
high dose i.v. immunoglobulins,38 could be useful for
their steroid-sparing effect. However, as there is not
enough good and safe evidence in support of these
drugs in childhood asthma, their use cannot yet be
recommended.
Conclusions
In most cases, bronchial asthma requires anti-
inflammatory treatment which should be started as
early as possible. Laitinen et al. demonstrated a
significant increase in eosinophils (p < 0.001),
lymphocytes (p < 0.001) and plasma cells (p < 0.001)
in bronchial mucosa, even in the mildest of asthmatic
patients with a diagnosis made between 2 and 12
months ago. Since asthma is a chronic disease, anti-
inflammatory therapy could be used for many years.
Thus, SCG and NED should be considered as a first-
line therapy because of their optimal safety profile.
Corticosteroids should be reserved for patients
whose symptoms are not completely controlled by
courses of at least 2-3 months with SCG or NED used
at dosages even higher than those conventionally
suggested. Inhaled steroids, when they are required
to control the disease, should be associated with SCG
or NED in order to reduce the steroid dose.
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